First-in-human phase 1 study of novel dUTPase inhibitor TAS-114 in combination with S-1 in Japanese patients with advanced solid tumors

Background This first-in-human phase 1 study assessed the safety of TAS-114, a novel deoxyuridine triphosphatase inhibitor, combined with S-1 to determine its maximum tolerated dose (MTD) and recommended dose (RD). Methods In this dose-escalation study with a 3 + 3 design, TAS-114 and S-1 were concu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Invest New Drugs
Main Authors: Doi, Toshihiko, Yoh, Kiyotaka, Shitara, Kohei, Takahashi, Hideaki, Ueno, Makoto, Kobayashi, Satoshi, Morimoto, Manabu, Okusaka, Takuji, Ueno, Hideki, Morizane, Chigusa, Okano, Naohiro, Nagashima, Fumio, Furuse, Junji
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2018
Assuntos:
Phase I Studies
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6538570/
https://ncbi.nlm.nih.gov/pubmed/30511200
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-018-0697-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados